Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SHPG Shire (SHPG) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis Get Shire alerts: Email Address About Shire Stock (NASDAQ:SHPG) 30 days 90 days 365 days Advanced Chart Ad Unstoppable ProsperityMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a row! But – knowing what the options trading landscape looks like, and what you're up against is a must.So make sure you claim your free seat by clicking here now. Get Shire alerts:Sign Up Key Stats Today's Range$179.20▼$179.2050-Day Range$179.20▼$179.2052-Week Range$123.73▼$182.47VolumeN/AAverage Volume2.21 million shsMarket Capitalization$54.71 billionP/E Ratio11.83Dividend Yield0.19%Price TargetN/AConsensus RatingN/A Company OverviewShire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.Read More… Must-Know for Trading Options (Ad)Options are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a row! But – knowing what the options trading landscape looks like, and what you're up against is a must.So make sure you claim your free seat by clicking here now. Receive SHPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shire and its competitors with MarketBeat's FREE daily newsletter. Email Address SHPG Stock News HeadlinesShire horse rescued from cattle gridSeptember 20 at 5:51 PM | bbc.co.ukSHPG Historical DataOctober 15, 2023 | investing.comMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a row! But – knowing what the options trading landscape looks like, and what you're up against is a must.September 20, 2024 | Unstoppable Prosperity (Ad)Shire Stock Hits New 52-Week High (SHPG)March 30, 2023 | thestreet.comEthiopia's Tigray conflict: Nasa shows how a war zone faded from space - BBCOctober 19, 2022 | bbc.comEthiopia civil war: Hyenas scavenge on corpses as Tigray forces retreat - BBCOctober 18, 2022 | bbc.comEthiopia civil war: Federal army seizes strategic city of Shire - Yahoo NewsOctober 18, 2022 | news.yahoo.comEthiopian war in Tigray intensifies as government soldiers capture strategic Shire - The Washington PostOctober 17, 2022 | washingtonpost.comSee More Headlines SHPG Stock Analysis - Frequently Asked Questions How were Shire's earnings last quarter? Shire plc (NASDAQ:SHPG) released its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.58 by $0.28. The business's quarterly revenue was up 5.4% on a year-over-year basis. What other stocks do shareholders of Shire own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shire investors own include Gilead Sciences (GILD), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Walt Disney (DIS) and Johnson & Johnson (JNJ). Company Calendar Last Earnings4/26/2018Today9/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SHPG CUSIPN/A CIK936402 Webwww.shire.com Phone353-1609-6000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)$15.15 Trailing P/E Ratio11.83 Forward P/E Ratio11.88 P/E Growth1.54Net Income$4.27 billion Net Margins30.63% Pretax MarginN/A Return on Equity12.70% Return on Assets7.06% Debt Debt-to-Equity Ratio0.36 Current Ratio0.92 Quick Ratio0.51 Sales & Book Value Annual Sales$15.16 billion Price / Sales3.61 Cash Flow$22.71 per share Price / Cash Flow7.89 Book Value$119.43 per share Price / Book1.50Miscellaneous Outstanding Shares305,280,000Free FloatN/AMarket Cap$54.71 billion OptionableOptionable Beta0.87 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:SHPG) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shire plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shire With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.